TMEM185A

Across TCGA pan-cancer cohorts, TMEM185A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM185A data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM185A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM185A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, HNSC, and LIHC are the cancer types where TMEM185A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.130	0.720	<.001	48	view →
HNSC	OS	Median	All	0.176	0.685	.024	24	view →
LIHC	OS	Median	All	0.184	0.786	<.001	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.477	0.701	.016	6	view →
SKCM	DFS	Median	All	1.000	0.732	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM185A–BLCA (OS)

Open the BLCA breakdown →